Testing cognition in clinical drug trials for Alzheimer's disease
About this webinar
The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060. Not only is there no cure at this point, but current treatments haven’t been successful, and clinical trials to develop new therapeutic interventions keep failing.
What’s holding back novel treatment option breakthroughs?
The cognitive scales used in most clinical trials aren’t ideal for the targeted patient cohorts, a significant reason that 98% of phase II and III clinical trials have failed.
This webinar examines the need for more thoughtful approaches to cognitive testing in clinical drug trials for AD.
You’ll learn:
- Why popular assessment tools fail to accurately test cognitive functioning in AD
- Strategies for selecting the most reliable, valid and sensitive scales to assess cognitive functioning in clinical trials for AD
- When to choose analog versus digital testing
- Ways to advance AD research and drug development by employing better endpoint measures
Did you enjoy this webinar?
Access more Pearson Pharma Services webinars like Finding the best metrics for pediatric neurogenetic trials featuring Drs. Shapiro, Eisengart, and Harmatz.
Speaker
John Harrison, PhD
Chief Scientific Officer, Scottish Brain Sciences
Dr. John Harrison is an acknowledged cognition expert whose main professional interest is in helping people understand, maintain, and enhance their cognitive skills. In the past 25 years, he has assisted more than 80 CNS drug development organizations with the selection and successful integration of cognitive testing into therapeutic development programs. He is an Associate Professor with the AUmc Alzheimer Center and Visiting Professor at King’s College London. He holds Chartered Psychologist status and has authored/co-authored more than 100 books and scientific articles.
